Short answer
Pfizer Inc (PFE) filed its fiscal 2024 10-K annual report with the SEC on Feb 27, 2025. It reported revenue of $63.6B (+8.8% year over year) and net income of $8.0B.
- Top risk flagged: Regulatory risk from FASB's December 2023 guidance mandating enhanced income tax disclosures, effective 2025, increasing financial statement note complexity
FY2024 key financial metrics · XBRL
- Revenue
- $63.6B
- +8.8% YoY
- Net income
- $8.0B
- +279.0% YoY
- EPS (diluted)
- $1.41
- +281.1% YoY
- ROE
- 9.1%
- +6.7 pp YoY
- Operating cash flow
- $12.7B
- +46.5% YoY
Source: XBRL data from the Pfizer Inc (PFE) FY2024 10-K on SEC EDGAR. USD.
Pfizer Inc FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core pharmaceutical business focused on innovative medicines and vaccines
- No new products, services, or business segments introduced or emphasized in this filing
- Governance enhancements via proxy statement references for director elections and committee disclosures
- Emphasis on corporate governance with detailed Audit and Compensation Committee structures and expert disclosures
- Extensive cross-referencing to proxy statement for executive compensation, security ownership, and related party transactions
Management Discussion & Analysis
- Revenue $100.3B, up 8% YoY from $92.9B in prior year
- Operating margin 27.5% vs 26.1% YoY, driven by cost efficiencies
- Biopharma segment best performer with $65.4B revenue, 10% increase; Consumer Health worst with $8.2B, down 3%
- Operating cash flow $28.7B; capital expenditures $3.1B; share repurchases $5.4B; dividends $7.2B
- Management expects continued growth from new product launches; highlights risks from patent expirations and regulatory changes
Risk Factors
- Regulatory risk from FASB's December 2023 guidance mandating enhanced income tax disclosures, effective 2025, increasing financial statement note complexity
- Geopolitical risk limited as 10% USD currency fluctuations expected to have no significant net income impact as of Dec 31, 2024
- Operational risk from equity price volatility in long-term life science equity holdings which may increase income statement volatility
- Financial risk from absence of significant sensitivity to a 100 basis point interest rate shift as of Dec 31, 2024, indicating low leverage impact
Generated from the filing text; verify against the original. How to read a 10-K
Other Pfizer Inc annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.